Danaher(US:DHR) Prnewswire·2025-09-09 12:00Core Viewpoint - Danaher Corporation is facing a securities fraud lawsuit alleging that the company misled investors about the sustainability of its bioprocessing division's growth during the COVID-19 pandemic, leading to artificially inflated stock prices [2]. Group 1: Legal Allegations - A U.S. District Judge has allowed key claims in a securities fraud lawsuit against Danaher, its CEO, and CFO to proceed, indicating that the lawsuit alleges false claims about revenue sustainability from January 2022 to October 2023 [2]. - The lawsuit claims that Danaher misrepresented the demand for its bioprocessing division, stating that revenues were sustainable while knowing that demand was declining and customers were relying on inventory stockpiles [2]. - Company insiders reportedly sold over $73 million in Danaher stock during the period when these misleading statements were made [2]. Group 2: Market Impact - Following the revelation in October 2023 that revenues from the bioprocessing division would decline, Danaher's stock experienced a 6% drop [2].